期刊文献+

小细胞肺癌血清细胞因子的表达及其诊断价值 被引量:6

Evaluation of Serum Cytokines in Small Cell Lung Cancer and Its Clinical Significance
在线阅读 下载PDF
导出
摘要 背景与目的已有的研究表明:小细胞肺癌(small cell lung cancer,SCLC)患者可出现血清细胞因子表达水平的变化,本研究通过检测SCLC患者血清中细胞因子的差异改变,探讨其在SCLC中的诊断价值。方法首先使用Reybiotech G6/G7细胞因子芯片对4例SCLC患者、4例健康人和4例炎症患者血清进行细胞因子差异表达筛查,进一步应用酶联免疫吸附法(ELISA试剂盒)对197例SCLC患者、180例正常对照血清以及97例炎性病变患者血清进行验证。结果芯片检测120种细胞因子,从有明显差异的细胞因子中选出最有研究价值的4种进行验证,包括尿激酶型纤溶酶原激活剂受体(urokinase plasminogen activator receptor,uPAR)、人瘦素(Leptin)、巨噬细胞刺激蛋白(macrophage stimulating protein α,MSP-α)和巨噬细胞炎症蛋白1β(macrophage inammatory protein1β,MIP-1β)。采用ELISA法验证上述结果,SCLC患者血清uPAR较健康人群以及炎症患者增高(P<0.05),诊断的敏感度为52.93%,特异度为83.36%。Leptin在无体重变化SCLC组较健康人群以及炎症患者增高,诊断的敏感度为50.11%,特异度86.77%;而Leptin在体重下降组较对照组无明显差异。此外,血清MSP-α、MIP-1β水平在三组之间比较无明显差异。结论血清uPAR升高在SCLC中具有一定的诊断价值,而Leptin在无体重变化的SCLC中可能具有诊断意义。 Background and objective It has been proven that serum cytokines could be changed in the early stage of patients with small cell lung cancer (SCLC). e current research investigates the di erent changes of cytockines and searches for potential biomarkers to improve the situation of the early diagnosis of SCLC. Methods e di erential expression cytokines were detected using Reybiotech G6/G7 analysis of microarrays in the serum of 4 SCLC patients, 4 normal controls, and 4 phlegmonosis controls. e di erential cytokines were con rmed by enzyme-linked immunosorbentassay (ELISA) in 197 SCLC patients, 180 normal controls, and 97 phlegmonosis controls. Results e levels of the 4 most valuable biomarkers in SCLC, including Leptin, MSP-α, uPAR, and MIP-1β, were signi cantly higher than that in the other groups with microaaray screening (P0.05). e ELISA results showed that the uPAR are much higher in SCLC patients than that in the controls, in which the diagnostic sensitivity and speci city were 52.93% and 83.36%, respectively. e Leptin level was signi cantly higher in SCLC patients who do not have obvious body weight lost, whereas no di erence were found in the SCLC who have obvious body weight lost compared with control groups. e diagnostic sensitivity and speci city of Leptin are 50.11% and 86.77%. e MSP-α and MIP-1β level have no signi cant di erence among the three groups. Conclusion e uPAR elevated level is signi cant in indicating SCLC diagnoses. e Leptin may be associated with SCLC in patients who do not have a change in weight.
出处 《中国肺癌杂志》 CAS 北大核心 2012年第1期11-16,共6页 Chinese Journal of Lung Cancer
关键词 细胞因子 肺肿瘤 诊断 Cytokines Lung neoplasms Diagnosis
  • 相关文献

参考文献25

  • 1Van Dyke AL, Cote ML, WenzlaffAS, et al. Cytokine and Cytokine receptor single-nudeotide polymorphisms predict risk for non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev 2009,18 (6): 1829-1840.
  • 2Yee J, Sadar MD, Sin DD, et al. Connective Tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol, 2009, 10(17): 2787-2792.
  • 3Coussens LM, Werb Z. Inflammation and cancer. Nature, 2002, 420(6917): 860-867.
  • 4Stab1 A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res, 1994, 54(11): 3066-3071.
  • 5Morita Y, Hayasbi Y, Wang Y, et al. Expression of urokinase-type plasminogen activator receptor in hepatoceUular carcinoma. Hepatology, 1997, 25(4): 856-861.
  • 6Mohanam S, Go Y, Sawa),a R, et al. Elevated levels of urokinase-type plasminogen activator and its receptor during tumor growth in viva. IntJ Oncol, 1999, 14(1): 169-174.
  • 7Raguso CA, Guinot SL, Janssens JP, et al. Chronic hypoxia:common traits be- tween chronic obstructive pulmonary disease andaltitude. Curt Opin Clin Nutr Metab Care, 2004, 7(4): 411-417.
  • 8Kanen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA, 1996, 93(12): 5793-5796.
  • 9Pal R, Lin C, Tran T.et al. Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation. Biochem Biophys Res Commun, 2005, 331 (4): 984-992.
  • 10Somasundar P, McFadden DW, Hileman SM, et al. Leptin is a growth factor in cancer.J Surg Res, 2004, 116(2): 337-349.

二级参考文献15

  • 1刘运秋,于立群,林江涛.检测肿瘤标志物ProGRP、NSE、CYFRA21-1、CEA对胸腔积液鉴别诊断价值的研究[J].中国肺癌杂志,2006,9(3):273-276. 被引量:18
  • 2Parkin DM, Bray F, FerlayJ, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
  • 3Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol, 2006, 6: 31.
  • 4Kawachi R, Nakazato Y, Takei H, et al. Clinical significance of preoperative carcinoembryonic antigen level for clinical stage I non-small cell lung cancer: can preoperative carcinoembr-yonic antigen level predict pathological stage? Interact Cardiovasc Thorac Surg, 2009, 9(2): 199-202.
  • 5Hatzakis KD, Froudarakis ME, Bouros D, et al. Prognostic value of serum tumor markers in patients with lung cancer. Respiration, 2002, 69(1): 25-29.
  • 6Emin Erbaycu A, Gunduz A, Batum O, et al. Pre-treatment and treatmentinduced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study. Arch Bronconeumol, 2010, 46(7): 364-369.
  • 7Zateska M, Szturmowicz M, Zych J, et al. Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival. Pneumonol Alergol Pol, 2010, 78 (1): 14-20.
  • 8Holdenrieder S, von Pawel J, Dankelmann E, et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-Line chemotherapy of small cell lung cancer. Clin Cancer Res, 2008, 14(23): 7813-7821.
  • 9Racil H, Saad S, Rouhou SC, et al. The value of tumor markers in pulmonary tuberculosis. Tunis Med, 2009, 87(5): 330-333.
  • 10Sheng SL, Huang G, Yu B, et al. Clinical significance and prognostic value of serum dickkopf-1 concentrations in patients with lung cancer. Clin Chem, 2009, 55(9): 1656-1664.

共引文献47

同被引文献49

  • 1席宝宇,张红娟,张妮,高胜男.姑息化疗对晚期肺癌患者细胞免疫功能及相关炎症因子水平的影响及护理对策[J].中国肿瘤临床与康复,2020,0(2):243-246. 被引量:11
  • 2阮永华,华海蓉,高倩,宋精玲,梁锐,金克炜.云锡矿粉诱发F344大鼠肺癌的病理改变[J].中华劳动卫生职业病杂志,2007,25(6):331-335. 被引量:6
  • 3Cook R M, Miller Y E, Bunn P A Jr. Small cell lung cancer: etiology, biology, clinical features, staging, and treatment [ J ]. Curr Probl Cancer, 1993, 17(2):69-141.
  • 4Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation [ J ]. Nature, 2008, 454 (7203) : 436 - 444.
  • 5Brenner D R, Boffetta P, Duell E J, et al. Previous lung diseases and lung cancer risk: a pooled analysis from the international lung cancer consortium[J]. Am J Epidemiol, 2012, 176(7) : 573 -585.
  • 6Szopinski J, yon Kleist S, Rowinska-Zakrzewska E, et al. Interferon gamma and Interleukin-2 secretion in whole blood cultures from small- cell lung cancer patients[J]. Tumour Biol, 2001, 22(2) : 72 -76.
  • 7Iwakura Y, Ishigame H, Saijo S, et al. Functional specialization of inter- leukin-17 family members[J]. Immunity, 2011, 34(2): 149 -162.
  • 8Hwang E S. Transcriptional regulation of T helper 17 cell differentiation [J]. YonseiMedJ, 2010, 51(4) : 484 -491.
  • 9Zheng Q, Tang Z Y, Xue Q, et al. Invasion and metastasis of hepato- cellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor[ J]. J Cancer Res Clin Oncol, 2000, 126 (11) : 641 -646.
  • 10Pi|lay V, Dass C R, Choong P F. The urokinase plasminogen activator receptor as a gene therapy target for cancer [ J ]. Trends Biotechnol, 2007, 25 ( 1 ) : 33 - 39.

引证文献6

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部